MedTrace Logo

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis

NCT00486434 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1176

Last updated 2019-04-26

Study results available
· View outcomes & findings →

Summary

The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoarthritis of the knee.

Conditions

Interventions

DRUG

SMC021 Oral Calcitonin

0.8mg SMC021 (Oral Calcitoinin) twice daily

DRUG

SMC021 Placebo

Placebo orally, twice daily

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Nordic Bioscience A/S

    lead INDUSTRY

Principal Investigators

  • Bente J Riis, M.D. · Nordic Bioscience A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
51 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Czechia
  • Denmark
  • Estonia
  • Hong Kong
  • Poland
  • Romania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00486434 on ClinicalTrials.gov